Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.650
-0.180 (-4.70%)
At close: Jul 30, 2025, 4:00 PM
3.690
+0.040 (1.10%)
After-hours: Jul 30, 2025, 7:37 PM EDT
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Vipin Garg |
Contact Details
Address: 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 United States | |
| Phone | 240 654 1450 |
| Website | altimmune.com |
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| Employer ID | 20-2726770 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vipin K. Garg Ph.D. | President, Chief Executive Officer and Director |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Andrew Shutterly M.S. | Principal Financial and Accounting Officer and Corporate Controller |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Tony Blandin B.S. | Vice President of Quality and Compliance Management |
| Raymond M. Jordt M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| Jun 26, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | EFFECT | Notice of Effectiveness |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 5, 2025 | UPLOAD | Filing |
| Feb 27, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |